In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Harvard Bioscience Inc (NASDAQ: HBIO) closed at $0.73 in the last session, up 1.06% from day before closing price of $0.72. In other words, the price has increased by $1.06 from its previous closing price. On the day, 0.66 million shares were traded. HBIO stock price reached its highest trading level at $0.7475 during the session, while it also had its lowest trading level at $0.7.
Ratios:
We take a closer look at HBIO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.81. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.04 whereas as Long-Term Debt/Eq ratio is at 0.52.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 32436162 and an Enterprise Value of 68404168. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37 while its Price-to-Book (P/B) ratio in mrq is 2.31. Its current Enterprise Value per Revenue stands at 0.783 whereas that against EBITDA is 13.716.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.52, which has changed by -0.6635514 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $2.38, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 38.01%, while the 200-Day Moving Average is calculated to be 41.69%.
Shares Statistics:
According to the various share statistics, HBIO traded on average about 6.49M shares per day over the past 3-months and 1116350 shares per day over the past 10 days. A total of 44.58M shares are outstanding, with a floating share count of 38.25M. Insiders hold about 14.20% of the company’s shares, while institutions hold 36.00% stake in the company. Shares short for HBIO as of 1763078400 were 1377735 with a Short Ratio of 0.21, compared to 1760486400 on 579892. Therefore, it implies a Short% of Shares Outstanding of 1377735 and a Short% of Float of 3.34.
Earnings Estimates
The dynamic stock of Harvard Bioscience Inc (HBIO) is currently attracting attention from 2.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.0, with high estimates of $0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.04 and $0.02 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.13 and $0.06.
Revenue Estimates
According to 2 analysts,. The current quarter’s revenue is expected to be $23.1M. It ranges from a high estimate of $23.4M to a low estimate of $22.8M. As of. The current estimate, Harvard Bioscience Inc’s year-ago sales were $24.56MFor the next quarter, 2 analysts are estimating revenue of $21.25M. There is a high estimate of $21.7M for the next quarter, whereas the lowest estimate is $20.8M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $86.2M, while the lowest revenue estimate was $85.6M, resulting in an average revenue estimate of $85.9M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $92.1M in the next fiscal year. The high estimate is $95.6M and the low estimate is $88.6M.
